Lung cancer is the most frequently diagnosed major cancer worldwide and the leading cause of death from cancer. Lung cancer is divided into two subgroups: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), accounting for 10-20% and 75% of lung cancer cases, respectively.The most common NSCLC histological subtypes are: adenocarcinoma (~35%), squamous cell carcinoma (~30%) and, large cell carcinoma (~10%). The separation in subgroups is essential with regard to treatment and prognosis. The majority of NSCLC patients only present with symptoms when the tumor reaches an advanced stage. The signs and symptoms in patients with lung cancer depend on the histology of the tumor, the extent of locoregional invasion as well as the location, size, and number of distant metastases. A minority of patients, about 15% present with an asymptomatic localized lesion discovered incidentally on chest radiography or CT scan. For localized NSCLC the 5-year survival rate is 70-85%, whereas for metastasized disease the 5- year survival rate is about 10%.

, ,
H.C. Hoogsteden (Henk) , H.J. de Koning (Harry)
Erasmus University Rotterdam
The studies in reported in this thesis were funded by The Netherlands Organization of Health Research and Development (ZonMw), the Dutch Cancer Society (KWF), and the Health Insurance Innovation Foundation (Innovatiefonds Zorgverzekeraars), Siemens Germany, Roche Diagnostics, G. Ph. Verhagen Stichting, Rotterdam Oncologic Thoracic Study (ROTS) Group, Erasmus Trust Fund, Tom en Josephine de Rijke fonds, Stichting tegen kanker, Vlaamse Liga tegen Kanker, and LOGO Leuven. This thesis was financially supported by: Chiesi, Glaxo SmithKline, Lilly, Novartis and Takeda.
Erasmus MC: University Medical Center Rotterdam

van 't Westeinde, S.C. (2012, June 21). Lung Cancer Screening and clinical implications . Erasmus University Rotterdam. Retrieved from